
News|Articles|July 1, 2025
Pulmonology Month in Review: June 2025
Author(s)Victoria Johnson
Fact checked by: Abigail Brooks, MA
June 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.
Advertisement
Advertisement
In June, asthma care and respiratory medicine were marked by pivotal updates, including new data reinforcing best practices and highlighting potential therapeutic breakthroughs across multiple respiratory and immune-mediated conditions. This month’s news underscores the importance of optimizing asthma management strategies, advancing biologic therapies for chronic airway diseases, and exploring novel interventions for challenging pulmonary disorders.
Related to this article

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Advertisement
Advertisement

